^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DP-9149

i
Other names: DP-9149, DP9149, DP 9149
Associations
Trials
Company:
Ono Pharma
Drug class:
GCN2 activator
Associations
Trials
almost2years
DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents (AACR 2023)
The ISR is a targetable vulnerability in oncogene addicted solid tumors. Upregulating the ISR by paradoxical activation of the ISR family member kinase, GCN2, by DP-9149 can be leveraged as a novel mechanism to cause anti-tumoral effects in solid tumors in vitro and in vivo, likely through the induction of an unresolved stress response. In particular, DP-9149 exhibited robust activity in RAS mutant cancers and in VHL-mutant renal cancers as a single agent and in combination with SOC agents in vivo.
Preclinical • Combination therapy • PARP Biomarker
|
VHL (von Hippel-Lindau tumor suppressor) • CASP3 (Caspase 3) • ATF4 (Activating Transcription Factor 4) • CASP7 (Caspase 7)
|
RAS mutation • VHL mutation
|
DP-9149